Posts by: Vanessa Pataia

News

Adding ipatasertib to standard treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly extended survival without disease worsening in a group of men whose tumors lack the PTEN protein, a Phase 3 ... Read more

June 4, 2020June 4, 2020

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

News

Urged by Prostate Cancer UK, NHS England is making Xtandi (enzalutamide) and Zytiga (abiraterone acetate) available during the COVID-19 pandemic for men with newly diagnosed advanced prostate cancer. Access to ... Read more

April 24, 2020April 24, 2020

FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

News

Myovant Sciences has filed an application with the U.S. Food and Drug Administration (FDA) seeking approval of relugolix to treat men with advanced prostate cancer. The new drug application (NDA) proposes a single ... Read more

March 6, 2020March 12, 2020

3 New miR Scientific Urine Tests Diagnose, Classify Prostate Cancer, Data Shows

News

The bioscience company miR Scientific has presented breakthrough data on three urine-based tests to detect and classify prostate cancer from RNA molecules, called small non-coding RNAs (sncRNAs). The first test, ... Read more